Side effects of retroviral gene transfer into hematopoietic stem cells
- PMID: 12511419
- DOI: 10.1182/blood-2002-07-2314
Side effects of retroviral gene transfer into hematopoietic stem cells
Abstract
Recent conceptual and technical improvements have resulted in clinically meaningful levels of gene transfer into repopulating hematopoietic stem cells. At the same time, evidence is accumulating that gene therapy may induce several kinds of unexpected side effects, based on preclinical and clinical data. To assess the therapeutic potential of genetic interventions in hematopoietic cells, it will be important to derive a classification of side effects, to obtain insights into their underlying mechanisms, and to use rigorous statistical approaches in comparing data. We here review side effects related to target cell manipulation; vector production; transgene insertion and expression; selection procedures for transgenic cells; and immune surveillance. We also address some inherent differences between hematopoiesis in the most commonly used animal model, the laboratory mouse, and in humans. It is our intention to emphasize the need for a critical and hypothesis-driven analysis of "transgene toxicology," in order to improve safety, efficiency, and prognosis for the yet small but expanding group of patients that could benefit from gene therapy.
Similar articles
-
Persisting multilineage transgene expression in the clonal progeny of a hematopoietic stem cell.Leukemia. 2002 Sep;16(9):1655-63. doi: 10.1038/sj.leu.2402619. Leukemia. 2002. PMID: 12200677
-
Retroviral vector-mediated gene transfer into hematopoietic cells: prospects and issues.J Hematother. 1992 Summer;1(2):155-66. doi: 10.1089/scd.1.1992.1.155. J Hematother. 1992. PMID: 1365023 Review.
-
Viral vectors for gene therapy of hematopoietic cells.Immunotechnology. 1997 Mar;3(1):3-19. doi: 10.1016/s1380-2933(96)00059-0. Immunotechnology. 1997. PMID: 9154464 Review.
-
Leukemias following retroviral transfer of multidrug resistance 1 (MDR1) are driven by combinatorial insertional mutagenesis.Blood. 2005 Jun 1;105(11):4235-46. doi: 10.1182/blood-2004-11-4535. Epub 2005 Feb 15. Blood. 2005. PMID: 15713797
-
Preclinical Testing of the Safety and Tolerability of Lentiviral Vector-Mediated Above-Normal Alpha-L-Iduronidase Expression in Murine and Human Hematopoietic Cells Using Toxicology and Biodistribution Good Laboratory Practice Studies.Hum Gene Ther. 2016 Oct;27(10):813-829. doi: 10.1089/hum.2016.068. Hum Gene Ther. 2016. PMID: 27431943
Cited by
-
Tailoring adipose stem cell trophic factor production with differentiation medium components to regenerate chondral defects.Tissue Eng Part A. 2013 Jun;19(11-12):1451-64. doi: 10.1089/ten.TEA.2012.0233. Epub 2013 Mar 28. Tissue Eng Part A. 2013. PMID: 23350662 Free PMC article.
-
MOLECULAR MEDICINE: Found in Translation.Med. 2021 Feb 12;2(2):122-136. doi: 10.1016/j.medj.2020.12.011. Epub 2021 Jan 12. Med. 2021. PMID: 33688634 Free PMC article. Review.
-
Decade-long safety and function of retroviral-modified chimeric antigen receptor T cells.Sci Transl Med. 2012 May 2;4(132):132ra53. doi: 10.1126/scitranslmed.3003761. Sci Transl Med. 2012. PMID: 22553251 Free PMC article. Clinical Trial.
-
Improved transduction of human sheep repopulating cells by retrovirus vectors pseudotyped with feline leukemia virus type C or RD114 envelopes.Blood. 2005 Jul 1;106(1):51-8. doi: 10.1182/blood-2004-11-4491. Epub 2005 Mar 17. Blood. 2005. PMID: 15774617 Free PMC article.
-
Correction of canine X-linked severe combined immunodeficiency by in vivo retroviral gene therapy.Blood. 2006 Apr 15;107(8):3091-7. doi: 10.1182/blood-2005-10-4057. Epub 2005 Dec 29. Blood. 2006. PMID: 16384923 Free PMC article.
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
